Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating an oral aripiprazole/escitalopram combination for major depressive disorder was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• aripiprazole/escitalopram combination (aripiprazole and escitalopram)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Major Depressive Disorder (MDD) | Phase 3 | Status: TERMINATED | Results posted: 2021-10-20